Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIP-rABVD vs CHOP/21 in Peripheral T Cell Lymphoma
NCT00970385Phase 3Completed
- Sponsor
- CHU Grenoble Alpes
- Start
- Jan 1995
- Primary completion
- Dec 2002
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 3 trial of etoposide, ifosfamide, Cisplatin micelle injection (HA132), pegylated liposomal doxorubicin, bleomycin in peripheral T-cell lymphoma (PTCL), sponsored by CHU Grenoble Alpes. Started Jan 1995; status: completed.
02
Drugs
etoposideifosfamideCisplatin micelle injection (HA132)pegylated liposomal doxorubicinbleomycin
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT00970385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00970385.